Cardiac involvement in hemochromatosis

Area of Science:

• Cardiology
• Genetics
• Internal Medicine

Background:

• Cardiac hemochromatosis, or primary iron-overload cardiomyopathy, is a significant and preventable cause of heart failure.
• It initially presents with diastolic dysfunction and arrhythmias, progressing to dilated cardiomyopathy in later stages.
• Diagnosis relies on elevated transferrin saturation and serum ferritin levels, with genetic testing for iron-related genes if secondary causes are excluded.

Purpose of the Study:

• To review the diagnostic modalities and therapeutic strategies for cardiac hemochromatosis.
• To highlight the importance of early detection and intervention for improving patient outcomes.

Main Methods:

• Comprehensive 2D and Doppler echocardiography for assessing cardiac function.
• Advanced imaging techniques like strain imaging and speckle-tracking echocardiography for early detection.
• Cardiac magnetic resonance imaging (CMR) with T2* relaxation times for quantifying myocardial iron.
• Genetic testing for HFE gene mutations and other iron-related proteins.
• Therapeutic phlebotomy and iron chelation therapy.

Main Results:

• Elevated transferrin saturation (>55%) and serum ferritin (>300 ng/mL) are key diagnostic markers.
• Echocardiography and CMR are crucial for evaluating cardiac involvement and monitoring treatment response.
• Untreated severe cardiac impairment leads to poor survival (<1 year).

Conclusions:

• Early and aggressive treatment of cardiac hemochromatosis can dramatically improve survival rates, approaching those of the general heart failure population.
• Multimodality imaging and timely iron reduction therapy are essential for managing this condition.